Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 12,563 Shares

Posted by Stanley Muller on Jan 16th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 12,563 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $5.10, for a total value of $64,071.30. Following the sale, the insider owned 650,298 shares of the company’s stock, valued at approximately $3,316,519.80. This represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total value of $127,653.45.
On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $56,900.25.
On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55.
On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total transaction of $24,770.02.
On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total value of $18,790.44.
On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total value of $34,451.03.
On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total value of $76,081.95.

Clene Price Performance

Shares of CLNN stock traded up $0.10 on Friday, reaching $5.21. 31,933 shares of the company were exchanged, compared to its average volume of 130,336. Clene Inc. has a one year low of $2.28 and a one year high of $13.50. The company has a 50-day moving average of $7.23 and a 200-day moving average of $6.44. The company has a market cap of $56.57 million, a price-to-earnings ratio of -1.54 and a beta of 0.87.

Clene (NASDAQ:CLNN – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, sell-side analysts predict that Clene Inc. will post -5.19 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. UBS Group restated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Friday, January 9th. Finally, Benchmark reaffirmed a “buy” rating on shares of Clene in a report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.60.

Get Our Latest Report on CLNN

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new position in Clene in the 3rd quarter worth $29,000. Jane Street Group LLC bought a new position in shares of Clene in the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. lifted its stake in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the period. Finally, Scoggin Management LP boosted its position in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares in the last quarter. Hedge funds and other institutional investors own 23.28% of the company’s stock.

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).